Progyny COO Cummings Sells 3,437 Shares for $109,000 — Here’s What That Means for Investors
Melissa B. Cummings, Chief Operating Officer of Progyny, Inc. (PGNY +0.22%), reported a sale of 3,437 shares of common stock on July 14, 2026. SEC Form 4 filing
Transaction summary
| Metric | Value |
|---|---|
| Shares sold | 3,437 |
| Transaction value | ~$109,056 |
| Post-transaction shares (directly held) | 69,934 |
| Post-transaction value | $2.26 million |
Transaction value based on SEC Form 4 weighted average sale price ($31.73); post-transaction value based on July 14, 2026, market close ($32.36).
Key questions
- What were the primary drivers behind this equity disposition?
The transaction was structured to address both personal liquidity and tax obligations. Specifically, 2,244 shares were sold pursuant to a Rule 10b5-1 trading plan established on Dec. 19, 2025, while Progyny withheld 1,193 shares to cover tax liabilities stemming from the vesting of restricted stock units. - How does this transaction affect the insider’s total exposure to Progyny?
While direct holdings decreased by 5% in this filing, Cummings maintains a significant equity position of 69,934 shares. This remaining stake represents a 0.0893% ownership interest in the company, valued at $2.26 million based on the market close on the transaction date. - What is the recent context of the stock’s performance?
Progyny shares were priced at $32.36 at the close of July 14, 2026, the day the transaction occurred. At that time, the company had delivered a total return of 38% over the preceding 12 months. As of July 15, 2026, market close, the stock was priced at $32.34.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-07-15) | $32.34 |
| Market Capitalization | $2.5 billion |
| Revenue (TTM) | $1.3 billion |
| Net Income (TTM) | $67.7 million |
Company Snapshot
- Progyny operates as a specialized benefits management platform, providing comprehensive fertility and family-building solutions to employers. It features a distinctive benefits plan architecture, personalized member support services, and access to a curated network of top-tier fertility specialists, complemented by its Progyny Rx pharmaceutical offering.
- The company generates revenue through a subscription-based benefits management model where employers contract with Progyny to provide fertility and family-building benefits to their employees, supplemented by revenue from pharmaceutical services and ancillary offerings.
- Progyny primarily serves mid-to-large employers across the United States seeking to offer comprehensive fertility and family-building benefits as part of their employee benefits packages, addressing the growing demand for specialized reproductive health coverage.
Progyny is a market-leading benefits management company with a $2.5 billion market capitalization, generating $1.3 billion in TTM revenue with $67.7 million in net income. The company has established a differentiated competitive position through its integrated platform combining benefits administration, personalized member services, and access to a selective network of fertility specialists, positioning it as a strategic partner for employers seeking to attract and retain talent through comprehensive family-building benefits.
What this transaction means for investors
COO Cummings’ sales were pretty run-of-the-mill transactions. Some of it covered withholding taxes generated from restricted stock units, and the rest came from structured, pre-planned sales. Investors shouldn’t worry too much about these sales — it wasn’t done in reaction to the stock’s price or its fundamentals.
As for Progyny’s stock, its share price has nearly doubled over the last few months after the company reported better-than-expected earnings and guidance in May. Despite losing one of its largest clients (suspected to be Amazon, though not confirmed), Progyny has rebounded nicely, delivering 1% sales growth in its most recent quarter, even though the customer accounted for 11 percentage points of a growth slowdown.
Meanwhile, Progyny’s margins have continued to improve, giving management the confidence to repurchase $200 million in shares, lowering its share count by 18% since 2024. Recently, another $200 million repurchase plan was put in place, which represents nearly 10% of its remaining shares. Progyny is a core holding for me, and I will continue adding to it over time. However, I’ll be watching customer concentration and a growing list of competitors very closely to see whether Progyny can gradually build a sustainable moat.
